Volume 4, Issue 8
While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.
Take our post-test to claim CME credits.
To read a companion newsletter click here
Podcast (ehiv): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS